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OBJECTIVES: Previous studies have established that etanercept
is cost-effective when used for the treatment of rheumatoid
arthritis (RA) following the failure of 2 DMARD therapies.
This analysis explores the use of etanercept after the failure
of a previous anti-tumor necrosis factor (anti-TNF) agent.
METHODS: A sequential Markov model was developed to
predict the costs and health outcomes associated with different
treatments for patients with RA in the UK. The model estimated
the cost-effectiveness of sequential anti-TNF therapies when
compared against a sequence containing no anti-TNF treatments
(i.e. solely DMARD therapies). In a separate analysis, etanercept
was compared against rituximab after the failure of a previous
anti-TNF. For each treatment, the initial, medium-term and long-
term effects on the Health Assessment Questionnaire (HAQ)
score were calculated. HAQ scores at each time period deter-
mined each patient’s utility (QALYs), resource use and mortality.
Effectiveness data (HAQ progression, serious adverse events and
mortality) were derived from the results from trials and pub-
lished literature. Various scenarios were assessed using different
interpretations of effectiveness data for sequential use of anti-
TNFs. Utility scores were converted from HAQ data using the
EQ-5D. Cost data were drawn from established national data-
bases. RESULTS: Patients who received two successive anti-TNF
therapies gained between 0.63 (when the initial HAQ change for
etanercept was assumed to be 0.51) and 0.76 (when the initial
HAQ change was assumed to be 0.40) additional QALYs com-
pared to the DMARD-only cohort. The incremental cost varied
between £11,300 and £13,600, resulting in the incremental cost-
effectiveness ratios (ICER) ranging between £17,916 and
£20,479. When etanercept was compared against rituximab after
the failure of another anti-TNF, the ICER ranged between £7290
and £9031. CONCLUSIONS: This study has demonstrated that
etanercept is a cost-effective treatment option for patients with
rheumatoid arthritis, even when it is used sequentially with other
anti-TNF agents.
PMS25
COST-EFFECTIVENESS OF RITUXIMAB (MABTHERA)
COMPARED WITHTNF INHIBITORS FORTHETREATMENT OF
RHEUMATOID ARTHRITIS (RA) IN POLAND
Plisko R1, Krzystek J1, Rys P1, Russel-Szymczyk M2,
Szkultecka-Debek M2, Szamotulska K3
1HTA Consulting, Krakow, Poland, 2Roche Polska,Warsaw, Poland,
3National Research Institute of Mother and Child,Warsaw, Poland
OBJECTIVES: To evaluate the cost-effectiveness of rituximab
compared with TNF inhibitors for the treatment of RA patients
following the failure of 2 DMARDs and 1 TNF inhibitor in
Polish setting. METHODS: A cost-utility approach was adopted,
evaluating the total direct National Health Fund costs and
QALYs. Baseline patient characteristics were based on the
REFLEX and DANCER phase III trials. A micro-simulation
model of 50 000 RA patients estimated lifetime Health Assess-
ment Questionnaire (HAQ) progression, QALYs and direct costs.
The starting time-point of the model was the failure of two
previous DMARDs. Two treatment options were compared.
Upon treatment failure it was assumed patients would follow an
identical lifetime treatment strategy consisting of: TRDM—
inﬂiximab, rituximab, leﬂunomide and palliative care or TTDM
—inﬂiximab, etanercept, leﬂunomide and palliative care. Ritux-
imab was assumed to be administered every 9 months to
responding patients. ACR response rates were taken from the
phase III RCTs and adjusted for placebo response. The initial
HAQ drop by ACR category and longterm HAQ progression
ware taken from the published literature. RESULTS: Annual
drug acquisition and administration costs were lower for TRDM
compared to TTDM. Discounted total lifetime direct NHF costs
were 216,460 pln and 233,734 pln for TRDM and TTDM
groups respectively. Total QALYs were 29,952 and 25,854 for
TRDM and TTDM, respectively. TRDM is a dominant therapy
over TTDM. CONCLUSIONS: The model predicted that
TRDM dominated options for RA patients who have failed
DMARD therapy, with higher estimated QALYs and lower NHF
costs. The results will be different when different TNF inhibitors
will be taken into account.
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OBJECTIVES: Recombinant human bone morphogenetic
protein (rhBMP2) is a novel biologic therapy that promotes
bone growth at the fracture site. We analyzed the cost-
effectiveness of rhBMP-2 in open tibia fractures in The Neth-
erlands. METHODS: An economic model comparing rhBMP-2
plus standard of care -consisting of soft tissue management and
intramedullary nailing- with standard of care alone. Clinical
data were drawn from the BMP-2 Evaluation for Surgery in
Tibial Trauma (BESTT) trial and treatment costs were taken
from Dutch national sources. Total costs were calculated as
direct plus indirect costs. Direct costs consisted of drug costs
and cost for complications. Indirect costs were calculated as
lost productivity times average annual salaries. Utility weights
were assigned to different grades (Gustillo IIIA and B) of open
tibia fractures to estimate the difference in quality-adjusted-life-
expectancy. We performed the analysis from payer’s and soci-
etal perspectives for a one-year time-horizon. RESULTS: In The
Netherlands, use of rhBMP-2 for grade III open tibia fractures
resulted in an incremental cost of €1,935 per patient and in
incremental cost-effectiveness ratio (ICER) of €27,587/QALY.
When indirect costs were included, rhBMP-2 treatment for
grade III open tibia fractures resulted in an incremental cost of
€400 per patient and an ICER of €5,708/QALY. CONCLU-
SIONS: From a payer’s perspective, rhBMP-2 is a cost-effective
treatment option in grade III open tibia fractures for the Dutch
health care systems.
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OBJECTIVES: The aim of this analysis was to evaluate cost
consequences of rituximab (RTX) treatment in rheumatoid
arthritis (RA) from the payer perspective, in a phase IV open-
label study conducted by Clalit Health Services, the largest
Israeli HMO, in collaboration with Roche Pharmaceuticals.
METHODS: Patients with prior inadequate response to disease-
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modifying anti-rheumatic drugs (DMARDs) or to both
DMARDs and anti-TNFs received the RA RTX regimen (1gx2).
The clinical outcome measure was moderate/good EULAR
response at 24 weeks. Responding patients were eligible to
re-treatment with RTX upon disease exacerbation after a
minimum of 48 weeks. Costs of RTX treatment (drug acquisition
& administration) were compared to average costs of the spared
anti-TNFs (inﬂiximab, etanercept or adalimumab) that would
have been provided otherwise to each patient until RTX
re-treatment or end of follow-up (FU). Prices are based on Israeli
tariff before VAT. RESULTS: A total of 108 patients were
enrolled. Sixty-seven DMARDs failures (62%), 41 DMARDs
and anti-TNF failures (38%). At time of analysis (January 2008),
89 patients completed a minimum of 24 weeks follow-up (FU).
Three dropped out in less than 24 weeks. Median FU: 75 weeks.
35/89 patients (39%) received re-treatment with RTX at a
median of 63 weeks. A total of 37/89 patients (42%) were (at
time of analysis) still on FU with no other treatment (median FU:
93wks). Average cost in Israel of anti-TNF treatment: NIS1955
(~560$)/week Cost of RTX (2g): NIS34,448 (~$9,840). The total
saving per patient (up to data cutoff) results in NIS85,258
(~$24,360). Overall cost saving during this period for 92 patients
was NIS7,844 million (~$2,241,120). This sum is still an under-
estimation since 42% of the patients still require no further
treatment, and continue to spare anti-TNF therapy. CONCLU-
SIONS: From the payer perspective, RTX treatment is a signiﬁ-
cant cost-saving alternative for patients with RA in the Israeli
public health care setting.
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OBJECTIVES: RA is a chronic disease associated with a signiﬁ-
cant use of health care resources, imposing a substantial eco-
nomic burden to patients, health insurance and to society in
France. The objective of the present study was to assess the use of
direct medical resources excluding drug costs by RA patients in
France and to derive original costing data per level of disease
activity. METHODS: An advanced standard costing approach
was performed in collaboration with a panel of expert clinicians
highly experienced in the management of RA in France. Four
categories of disease activity were deﬁned according to DAS28
thresholds: patients (pts) achieving remission (DAS <2.6), pts not
achieving remission (DAS 2.6), pts achieving low disease activ-
ity state (LDAS; DAS 3.2) and pts not achieving LDAS (DAS
>3.2). Eight resource utilization items were deﬁned: medical
visits, laboratory tests, hospitalization, imaging, physiotherapy,
nursing, adaptive aids and transportation. Resource utilization
and unit costs from the national payer perspective were collected
and simulated using distribution ranges for each item. Using a
simulation model, a computation of all costs distributions was
performed to estimate the overall costs per six months over a
2-year time horizon. RESULTS: Direct medical costs were esti-
mated per disease activity level. For pts achieving remission
during the ﬁrst 6 months, about 90% generated costs under
€1000, with costs estimated at €771 (SD = 199) per 6 months
and €511 (SD = 162) for each subsequent 6 months (p < 0.001).
For pts not achieving remission per 6 months, about 85% gen-
erated costs under €1500, with costs estimated at €1159 per 6
months (SD = 339). For pts achieving LDAS, costs were esti-
mated at €905 (SD = 263) per 6 months and €696 (SD = 240) for
each subsequent 6 months (p < 0.001). For pts not achieving
LDAS, costs were estimated at €1215 per 6 months (SD = 405).
Key costs drivers were medical visits, laboratory tests and trans-
portation. CONCLUSIONS: This cost of illness assessment pro-
vides precise and current estimates of medical direct costs per RA
disease activity in France, conﬁrming that RA imposes a substan-
tial economic burden. The ﬁndings suggest that achieving LDAS
or remission is associated with substantially lower RA medical
costs.
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OBJECTIVES: To estimate the cost savings in outpatient
medical resource use associated with diagnosing ﬁbromyalgia
during the four years after ﬁbromyalgia diagnosis. METHODS:
A questionnaire was created based on the medical resources use
from 2260 patients diagnosed with FM between January 1998
and March 2003 in the General Practice Research Database
(FF-GPRD) in United-Kingdom. Local experts were asked to
compare their own clinical practice to UK prescriptions and
resource use, over a period of four years before diagnosis to four
plus years after diagnosis using one year cross-sections. Poisson
loglinear regression models, published for the UK, allowed to
estimate the medical resources consumed if no diagnosis had
been established. The impact of diagnosis was evaluated for each
of these medical resources. Costs were calculated by multiplying
resource use with corresponding Spanish unit costs (€; 2008;
both public health care payer perspective and societal perspec-
tive including patient co-payments). RESULTS: This study con-
ﬁrms previously published results obtained for the UK and
France: whereas costs gradually increase before diagnosis, a
stagnation in costs increase occurs in the year after diagnosis,
subsequently followed by a moderate decrease afterwards. The
savings made as a result of ﬁbromyalgia diagnosis add up to
€421 per patient and per year from the health care system per-
spective and €432 from a societal point of view. Diagnostic tests,
referrals to specialists, GP visits and drugs represent respectively
42%, 29%, 15% and 14% of these savings, CONCLUSIONS:
Compared to a diagnosed ﬁbromyalgia patient, a not diagnosed
patient in Spain represents an incremental cost of €421 from the
health care payer perspective.
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OBJECTIVES: To estimate the costs savings in outpatient
medical resource use associated with diagnosing ﬁbromyalgia
during the four years after ﬁbromyalgia diagnosis, METHODS:
A French expert panel, involving 33 general practitioners (GPs)
and 27 rheumatologists, was questioned in 2007 by means of a
questionnaire describing the UK prescriptions registered in the
General Practice Research Database between January 1998 and
March 2003 (2260 ﬁbromyalgia patients). Participating experts
were asked to describe their clinical practice compared to the UK
prescriptions in terms of diagnostic tests, drugs, consultations
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